Gary, I think your framing continues to be right on point. If the UK submission is serving as the lead under Orbis, it would explain the silence, the coordination, and the absence of public-facing movement. Your reference to how long it took for agreement during the trial halt is a useful reminder. If those same regulators are operating in alignment now, it’s entirely possible the delay is strategic rather than procedural. And given how Orbis confidentiality works, we likely wouldn’t know until the UK moves first.
Doc Logic is right to clarify that a Biologics License Application is still legally required for U.S. approval, but what’s changed is the structure surrounding how that BLA can be submitted and reviewed. In June, the FDA launched the Commissioner’s National Priority Voucher program. It allows therapies that meet national health priorities—including serious cancers and advanced biologics like DCVax-L, to be reviewed in one to two months through a single day, multidisciplinary panel. Sponsors can use existing trial data, and only need to submit the CMC and draft labeling sixty days in advance.
So yes, the BLA is still technically required, but the process around it has been reshaped. What you described now matches directly to what this program enables. Orbis could be the quiet coordination mechanism, while CNPV gives FDA the domestic legal pathway to move quickly once that coordination is complete.
As for Advent and the MHRA, you’re absolutely right that Specials use and IFRs do not operate in a clinical trial silo, but that doesn’t mean they’re informal. They generate real-world data, batch release records, safety logs, treatment timelines, and physician reports. That information is often held by both the manufacturer and the treating institution, and it becomes part of the traceable GMP record. In the case of IFRs, UK physicians are required to justify clinical need and often report outcomes. This creates a body of real-world evidence that can be used to support broader authorization or label expansion.
So if NWBO has treated hundreds of patients under these frameworks, they’re not just building access, they’re accumulating structured data, quietly but legally. That data can reinforce the Phase 3 dataset, support CNPV acceleration, and backstop an Orbis-informed BLA.
Orbis could be guiding the coordination. CNPV could be enabling the domestic entry point. And MHRA may already be holding the key.
In the end, what you’ve outlined fits the map: Orbis for alignment, MHRA for lead authority, CNPV for execution, and Specials for silent validation. Silence might not mean delay. It might mean it’s all already in motion.
Bullish
Market Data 
Markets 
